U.S. Biotech Stock News

NYSE:GRND
NYSE:GRNDInteractive Media and Services

Grindr (GRND) Valuation Check As Shares Show Recent Gains But Longer-Term Weakness

Grindr (GRND) has drawn fresh attention after recent share moves, with the stock up about 10% over the past month but showing a 9% decline over the past 3 months. See our latest analysis for Grindr. At a share price of $12.42, Grindr’s 30-day share price return of 10.30% sits against a 90-day share price return decline of 8.94% and a 1-year total shareholder return decline of 30.50%, suggesting recent momentum is stabilising after earlier weakness. If Grindr’s moves have you thinking about...
NYSE:ESE
NYSE:ESEMachinery

Is It Too Late To Consider ESCO Technologies (ESE) After Its 80% One Year Rally?

If you are wondering whether ESCO Technologies at around US$288.77 is priced attractively or stretched, the starting point is understanding how that share price stacks up against different measures of value. The stock has delivered returns of 8.0% over 7 days, 4.2% over 30 days, 46.1% year to date and 80.4% over 1 year, with a 215.4% return over 3 years and 169.1% over 5 years. This puts recent valuation questions front and center for many investors. Recent coverage has focused on ESCO...
NYSE:AMT
NYSE:AMTSpecialized REITs

Is It Time To Reassess American Tower (AMT) After Recent Share Price Weakness?

With American Tower trading at US$167.27, many investors are asking a simple question: does this price reflect the real value of the business, or is the market mispricing it right now? Recent share price moves have raised that question even more, with the stock showing a 7.4% decline over the past week, a 12.0% decline over the past month, a 4.3% decline year to date, and a 17.6% decline over the last year. Alongside these moves, ongoing attention on interest rate trends, real estate...
NYSE:TIC
NYSE:TICProfessional Services

A Look At TIC Solutions (TIC) Valuation After Earnings CEO Transition Guidance And Buyback Announcement

TIC Solutions (TIC) shares are reacting to a busy March 12 update, as the company reported fourth quarter and full year 2025 earnings, issued 2026 revenue guidance, announced CEO succession plans, and introduced a US$200 million buyback. See our latest analysis for TIC Solutions. Despite the earnings release, 2026 revenue guidance, CEO transition, and US$200 million buyback, TIC Solutions’ recent share price performance has been weak. The 30 day share price return is 20%, and the 1 year total...
NYSE:CWEN.A
NYSE:CWEN.ARenewable Energy

Is It Too Late To Consider Clearway Energy (CWEN.A) After A 45% One Year Gain?

Wondering if Clearway Energy is still reasonably priced after its recent run, or if the market has already baked in the story? This article focuses squarely on what you are paying for versus what you are getting. The stock last closed at US$39.09, with returns of 4.3% over 30 days and 21.7% year to date. The 1 year return sits at 45.3% and the 5 year return at 94.7%. Recent headlines around the renewable power space have kept attention on companies like Clearway Energy, with investors...
NYSE:VG
NYSE:VGOil and Gas

Is Venture Global (VG) Quietly Recasting Its LNG Strategy With Flexible Deals And Hollywood-Style Branding?

In March 2026, Venture Global, Inc. and Vitol signed a binding agreement for Vitol to purchase about 1.5 million tonnes per annum of U.S. LNG from Venture Global’s portfolio for five years starting in 2026, alongside Venture Global’s launch of its first national “Unstoppable Energy” advertising campaign narrated by Billy Bob Thornton. This combination of a new flexible LNG offtake deal and a high-profile brand campaign highlights how Venture Global is trying to broaden its customer reach...
NasdaqGM:TTD
NasdaqGM:TTDMedia

Nasdaq Warning Puts Trade Desk Governance And Valuation Gap In Focus

The Trade Desk received a formal notice from Nasdaq that it is not in compliance with exchange rules for audit and compensation committee composition following a recent board resignation. The company has stated its intention to regain compliance, but specific timing and steps have not been detailed publicly. This governance issue arrives at a time when the shares, at $21.97, reflect extended share price pressure and weaker recent returns. NasdaqGM:TTD is facing this governance setback...
NYSE:INGR
NYSE:INGRFood

AI Protein Push and Boardroom Shift Might Change The Case For Investing In Ingredion (INGR)

In recent days, Ingredion announced a global R&D partnership with Shiru to develop AI-discovered functional proteins and next-generation prebiotics, while also declaring a US$0.82 quarterly dividend and naming long-time executive Jason Payant as interim CFO from April 1, 2026. At the same time, the boardroom is evolving as long-serving director Gregory B. Kenny retires and former Glanbia chief executive Siobhán Talbot joins, potentially reshaping governance and expertise around Ingredion’s...
NYSE:CQP
NYSE:CQPOil and Gas

Cheniere Energy Partners Expansions And CPC Deal Shape Long Term Outlook

Cheniere Energy Partners (NYSE:CQP) has received key regulatory approvals to expand LNG export capacity at its Sabine Pass and Corpus Christi facilities. The company has signed a new long term LNG supply contract with Taiwan’s CPC Corporation following capacity additions at Train 5. These developments add to recent capacity milestones and extend Cheniere’s contracted export profile beyond earlier discussions focused on valuation and broad LNG market shifts. Cheniere Energy Partners, a major...
NYSE:UAMY
NYSE:UAMYMetals and Mining

Assessing United States Antimony (UAMY) Valuation After Full Year 2025 Revenue Surge And Wider Losses

United States Antimony (UAMY) drew fresh attention after reporting full year 2025 results, with sales of US$39.26 million compared with US$14.94 million a year earlier, alongside a wider net loss of US$4.34 million. See our latest analysis for United States Antimony. The earnings release appears to have coincided with building momentum, with a 27.52% 1 month share price return and a 55.43% 3 month share price return, while the 1 year total shareholder return is very large. If this kind of...
NYSE:BSX
NYSE:BSXMedical Equipment

Will Conference Focus on Cardiovascular Platforms and FARAPULSE, WATCHMAN Shape Boston Scientific's (BSX) Narrative?

Earlier in March 2026, Boston Scientific presented at the Life Science Intelligence Summit, featuring senior leaders including Vice President Isaac Knoot and Chief Medical Officers Michael R. Jaff and Brad Sutton discussing global business services and peripheral interventions. The conference appearances came shortly after investors focused on differences across divisions, including electrophysiology versus cardiovascular growth drivers such as FARAPULSE, WATCHMAN and the Penumbra...
NYSE:VST
NYSE:VSTRenewable Energy

Is Vistra (VST) Using PJM’s Co‑Location Rules Fight To Sharpen Its Data Center Strategy?

Vistra Corp. recently filed a protest with the Federal Energy Regulatory Commission, arguing that PJM Interconnection’s compliance plan on co-located facilities conflicts with a prior Commission order intended to support reliable, affordable development in the PJM region. The company warns that PJM’s proposed ambiguity on transition rules, delayed implementation until 2029, and complex capacity rights framework could slow integration of co-located projects critical for data centers and...
NYSE:O
NYSE:ORetail REITs

Realty Income Term Loan Reshapes Debt Mix For Community Power Deal

Realty Income (NYSE:O) closed a $694 million long term unsecured term loan with Goldman Sachs. The facility supports a municipal prepay transaction for San Diego Community Power, tied to community power infrastructure. The structure uses long dated, fixed rate financing and cross currency swaps to target a lower blended cost of debt. Realty Income, trading at $60.06, is adding this Goldman Sachs term loan to its funding toolkit at a time when its 1 year return stands at 12.2% and its 5 year...
NYSE:EVR
NYSE:EVRCapital Markets

Is Evercore’s Biotech Banking Push Quietly Redefining Its Core Strategy for EVR?

Earlier in March, Evercore announced the hire of David Ke as a senior managing director in its equity capital markets group focused on biotechnology, and the firm recently participated in the 2026 Life Science Intelligence Summit through a healthcare investment banking presentation by Bennett Blau. These developments highlight Evercore’s growing emphasis on healthcare and biotechnology advisory and capital-raising capabilities, reinforcing its presence in life sciences investment...
NYSE:LVS
NYSE:LVSHospitality

A Look At Las Vegas Sands (LVS) Valuation As Recent Share Price Momentum Cools

Stock performance context for Las Vegas Sands Las Vegas Sands (LVS) has attracted fresh attention as investors reassess casino and resort operators, with the stock recently closing at US$54.17 and showing mixed returns over the past year and multi year periods. Over the past month, Las Vegas Sands has recorded a 3% decline, while the past 3 months show an 18.3% negative return. Year to date, the stock is down 16.9%, although the 1 year total return stands at 37.2%. Looking at a longer window,...
NasdaqGS:WDAY
NasdaqGS:WDAYSoftware

A Fresh Look At Workday (WDAY) Valuation After Recent Share Price Weakness

Workday stock performance snapshot Workday (WDAY) has been under pressure recently, with the share price down about 2% over the past week and roughly 41% over the past 3 months, while year-to-date returns sit near 38% lower. See our latest analysis for Workday. At a share price of US$127.07, Workday’s recent trend points to fading momentum. The 90 day share price return is 41.4% and the 1 year total shareholder return is 49.3% lower, indicating investors have reassessed both growth prospects...
NYSE:JNJ
NYSE:JNJPharmaceuticals

Johnson & Johnson Balances Dividend Growth Biotech Exits And Talc Risks

Johnson & Johnson (NYSE:JNJ) has approved another dividend increase, supported by what it reports as strong free cash flow. The company is rebalancing its portfolio, exiting stakes in several biotech partners, including former collaborators. A recent California court ruling in talc litigation reduced punitive damages while maintaining compensatory damages, and JNJ plans to appeal. Johnson & Johnson, a large healthcare group with operations spanning pharmaceuticals, medical technologies and...
NasdaqGS:ARM
NasdaqGS:ARMSemiconductor

Arm’s First AI Data Center Chip Tests Lofty Valuation And Growth Story

Arm Holdings (NasdaqGS:ARM) has introduced its first in-house AI data center chip, the AGI CPU. The chip is designed for AI workloads in data centers and was developed with Meta as a lead partner. The move expands Arm’s role from licensing semiconductor IP to offering its own production silicon. The launch targets the growing demand for AI infrastructure across large technology platforms. Arm has long been known for designing energy efficient processor architectures that sit inside...
NYSE:UBER
NYSE:UBERTransportation

Uber And Ibotta Partnership Highlights Retail Media Potential For Investors

Uber Technologies (NYSE:UBER) has entered a multi year exclusive digital promotions partnership with Ibotta across the U.S. The agreement embeds personalized promotions and coupons into Uber Eats and is expected to extend across the Uber and Postmates apps. The partnership connects consumer packaged goods brands directly with shoppers at the point of purchase inside Uber’s delivery ecosystem. For Uber Technologies, this move fits directly into its push beyond ride hailing into grocery and...
NYSE:TEVA
NYSE:TEVAPharmaceuticals

How Investors May Respond To Teva (TEVA) Advancing TEV ‘325 In Biologics For Inflammatory Diseases

Biolojic Design recently announced that TEV ‘325, a multibody targeting IL-13 and TSLP for TH2-driven inflammatory diseases, achieved a preclinical milestone in its collaboration with Teva, triggering milestone payments and confirming Teva’s exclusive global development and commercialization rights. This milestone underscores Teva’s progress in innovative biologics, adding scientific and commercial depth to its inflammatory disease pipeline alongside its established generics and branded...
NYSE:EDU
NYSE:EDUConsumer Services

A Look At New Oriental Education & Technology Group (NYSE:EDU) Valuation After Recent Mixed Share Price Performance

Recent performance snapshot for New Oriental Education & Technology Group (EDU) New Oriental Education & Technology Group (NYSE:EDU) has attracted attention after a 2.2% move over the past day, set against mixed recent returns that include a 5.1% decline over the past month and a small gain over the past 3 months. See our latest analysis for New Oriental Education & Technology Group. That latest 2.2% daily share price gain comes after a softer patch, with a 30 day share price return of 5.1%...
NYSE:EPR
NYSE:EPRSpecialized REITs

Assessing EPR Properties (EPR) Valuation After Recent Share Price Pullback

Event context and recent share performance EPR Properties (EPR) has attracted investor attention after recent trading left the shares about 1.7% lower on the day and roughly 10% lower over the past week. Over the past month, the stock shows a decline of about 16%. The past 3 months and year to date have been comparatively steadier, with total return over the past year modestly positive. See our latest analysis for EPR Properties. The recent 16.1% 1 month share price decline has pulled...
NasdaqGS:SEIC
NasdaqGS:SEICCapital Markets

Is Ranchland’s Mandate a Subtle Turning Point in SEI’s Outsourcing Strategy Narrative (SEIC)?

Ranchland Capital Partners recently selected SEI Investments to provide fund administration and investor services for its alternative fund offerings, outsourcing key operational functions to SEI’s technology-enabled platform. This mandate underscores SEI’s growing role as an outsourced partner to alternative asset managers, reinforcing its focus on scalable technology, back-office efficiency, and long-term client relationships. We’ll now examine how supporting Ranchland’s alternative fund...
NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

Is It Too Late To Revisit Viking Therapeutics (VKTX) After Its Multi Year Surge?

Wondering if Viking Therapeutics at around US$33.20 is still offering value after a strong multi year run, or if the easy gains are already behind it. The stock has seen a 1% decline over the past week and a 3.7% decline over the last month, even with a 26% return over the past year and a very large gain over five years. Recent attention on Viking Therapeutics has been driven by its role in the pharmaceuticals and biotech space. In this area, clinical progress, partnerships, or regulatory...